Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 146

Sort by

Sort Order Select

Journal Articles

An integrative prognostic model for transplant outcomes in myelofibrosis

Blood (2025) 146 (Supplement 1): 912.

https://doi.org/10.1182/blood-2025-912

Published: 2025

Journal Articles

The need for a subsequent HCT is a late & continuous risk and with significant impact in overall survival in haemoaglobinopathies: Real-world data from 2000–2022. an analysis of the european society for blood and marrow transplantation (EBMT) hemoglobinopathy working party.

Josu de la Fuente, Donatella Baronciani, Mathilde Fekom, Arnaud Dalissier, Marco Zecca, Franco Locatelli, Giorgio La Nasa, Raffaella Cerretti, Tariq Ghafoor, Giuseppe Visani, Hakan Ozdogu, Fabio Ciceri, Ashrafsadat Mousavi, Sandrine Bremathas, Selim Corbacioglu, Emanuele Angelucci

Blood (2025) 146 (Supplement 1): 178.

https://doi.org/10.1182/blood-2025-178

Published: 2025

Journal Articles

Outcomes of allogeneic hematopoietic stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A registry-based study from the EBMT-LWP

Blood (2025) 146 (Supplement 1): 1842.

https://doi.org/10.1182/blood-2025-1842

Published: 2025

Journal Articles

Late recurrence of transfusion dependent thalassemia 30 years after transplantation

Emanuele Angelucci, Stella Santarone, Luca Malcovati, Massimiliano Gambella, Anna Maria Raiola, Simona Geroldi, Valeria Maria Pinto

Blood (2025) 146 (Supplement 1): 7789.

https://doi.org/10.1182/blood-2025-7789

Published: 2025

Journal Articles

Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis

Blood (2025) 146 (8): 1011–1029.

https://doi.org/10.1182/blood.2024027197

Published: 2025

Includes: Supplemental data

Journal Articles

How I manage iron overload in the hematopoietic cell transplantation setting

Emanuele Angelucci

Blood (2025) 145 (4): 372–382.

https://doi.org/10.1182/blood.2023022500

Published: 2025

Journal Articles

Risk Assessment of Complications Prevalence in Italian Chelated Transfusion Dependent Thalassemia Patients

Angela Vitrano, Massimiliano Copetti, Annarita Armaroli, Emanuele Angelucci, Aurelio Maggio

Blood (2024) 144 (Supplement 1): 3856.

https://doi.org/10.1182/blood-2024-199762

Published: 2024

Journal Articles

Age Is a Crucial Determinant of GFRS with Incidence of Severe Chronic GVHD Reducing over Time in Haemopoietic Cell Transplantation for Transfusion Dependent Thalassaemia: Real World Data from 2010-2021. an Analysis of the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Working Party

Donatella Baronciani, Josu de la Fuente, Jacques-Emanuel Galimard, Arnaud Dalissier, Ashrafsadat Mousavi, Akif Yesilipek, Hasan Hashem, Gulyuz Ozturk, Franco Locatelli, Ali Alahmari, Javid Gaziev, Ali Bülent Antmen, O. Alphan Kupesiz, Tunc Fisgin, Giorgio La Nasa, Arjan C. Lankester, Eugene Goussetis, Sandrine Bremathas, Emanuele Angelucci

Blood (2024) 144 (Supplement 1): 2136.

https://doi.org/10.1182/blood-2024-208421

Published: 2024

Journal Articles

Eltrombopag Added to Standard Immunosuppressive Treatment Improves Long-Term Outcomes As Front-Line Therapy for Severe Aplastic Anemia: Final 2-Year Analysis of EBMT-Saawp Race Study

Antonio M Risitano, Simona Iacobelli, Austin G. Kulasekararaj, Marleen Van Os, Sophie Terwel, Morag Griffin, Constantijn J.M. Halkes, Christian Recher, Fiorenza Barraco, Edouard Forcade, Carlos Vallejo, Beatrice Drexler, Jean-Baptiste Méar, Alexander Smith, Emanuele Angelucci, Reinier Raymakers, Marco R De Groot, Etienne Daguindau, Erfan Nur, Wilma Barcellini, Nigel H. Russell, Louis Terriou, Anna Paola Iori, Walter Barberi, Anna Sureda Balari, Isabel Sanchez-Ortega, Blanca Xicoy, Isidro Jarque Ramos, Jamie Cavenagh, Flore Sicre De Fontbrune, Camilla Frieri, Talha Munir, Jennifer Tjon, Suzanne Tavitian, Aline Praire, Laurence Clement, Florence Rabian, Luana Marano, Anita Hill, Elena Palmisani, Petra Muus, Serena Marotta, Fabiana Cacace, Marica Laurino, Jakob Passweg, Sr., Judith Marsh, Gerard Socie, Ghulam Mufti, Carlo Dufour, Regis Peffault De Latour

Blood (2024) 144 (Supplement 1): 302.

https://doi.org/10.1182/blood-2024-194699

Published: 2024

Journal Articles

Peripheral Blood Stem Cell Versus Bone Marrow Graft for Non-T-Depleted Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Patients with Secondary Acute Myeloid Leukemia in First Complete Remission: A Study from the ALWP/EBMT

Arnon Nagler, Allain-Thibeault Ferhat, Didier Blaise, Yener Koc, Emanuele Angelucci, Alessandro Busca, Jiri Pavlu, Stefania Bramanti, Maija Itäla-remes, Maria Aranzazu Bermudez Rodriguez, Jan Vydra, Alexander Kulagin, Ali Bazarbachi, Bipin N. Savani, Fabio Ciceri, Mohamad Mohty

Blood (2024) 144 (Supplement 1): 2190.

https://doi.org/10.1182/blood-2024-193936

Published: 2024

Journal Articles

Impact of Donor Type on Outcomes after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis

Blood (2024) 144 (Supplement 1): 3559.

https://doi.org/10.1182/blood-2024-193992

Published: 2024

Journal Articles

Prediction of Poor Survival after Hematopoietic Cell Transplantation in Myelofibrosis Using Machine Learning Techniques

Blood (2024) 144 (Supplement 1): 3558.

https://doi.org/10.1182/blood-2024-200237

Published: 2024

Journal Articles

Allogeneic Transplantation for Sickle Cell Disease Offers High Rates of Cure with Low Incidence of Severe Chronic GVHD in Both Children and Adults: Real World Data from 2010-2021. An Analysis of the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Working Party

Blood (2024) 144 (Supplement 1): 176.

https://doi.org/10.1182/blood-2024-207944

Published: 2024

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Retrospective Multicenter Analysis on 285 Procedures Performed between 2000 and 2020

Blood (2024) 144 (Supplement 1): 2186.

https://doi.org/10.1182/blood-2024-194320

Published: 2024

Journal Articles

Significant Growth in HCT Use for Haemoglobinopathies in the Last Decade Driven By Sickle Cell Disease across All Ages with Excellent Outcomes: An Analysis of EBMT Haemoglobinopathies Working Party

Blood (2024) 144 (Supplement 1): 2184.

https://doi.org/10.1182/blood-2024-208191

Published: 2024

Journal Articles

Better Outcome Following Younger Haploidentical Donor Versus Older Matched Unrelated Donor Transplant for Patients with Acute Myeloid Leukemia in First Remission: A Study from the Global Committee and Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Blood (2024) 144 (Supplement 1): 2180.

https://doi.org/10.1182/blood-2024-200423

Published: 2024

Journal Articles

Overcoming the Cost Barrier for Thalassemia Innovative Treatments

Angela Vitrano, Rita Barone, Antonino Giangreco, Rosario Di Maggio, Luca Castagna, Gianluca Forni, Emanuele Angelucci, Franco Locatelli, Aurelio Maggio

Blood (2023) 142 (Supplement 1): 5200.

https://doi.org/10.1182/blood-2023-180708

Published: 2023

Journal Articles

Outcomes of Patients with Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma from the LocoMMotion + MoMMent Studies

Blood (2023) 142 (Supplement 1): 4698.

https://doi.org/10.1182/blood-2023-181235

Published: 2023

Journal Articles

Durable Outcomes with Manageable Safety Leading to Prolonged Survival with Tagraxofusp for Treatment-Naive Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm: Updated Results from a European Named Patient Program

Emanuele Angelucci, Eric Deconinck, David Manteigas, Michael Zuurman, Marco Herling

Blood (2023) 142 (Supplement 1): 547.

https://doi.org/10.1182/blood-2023-178734

Published: 2023

Journal Articles

Impact of Fourth Methotrexate Dose in ATG-Cyclosporine GvHD Prophylaxis in HLA-Matched Unrelated HSCT: A GITMO Study

Blood (2022) 140 (Supplement 1): 10514–10516.

https://doi.org/10.1182/blood-2022-162853

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

An integrative prognostic model for transplant outcomes in myelofibrosis

The need for a subsequent HCT is a late & continuous risk and with significant impact in overall survival in haemoaglobinopathies: Real-world data from 2000–2022. an analysis of the european society for blood and marrow transplantation (EBMT) hemoglobinopathy working party.

Outcomes of allogeneic hematopoietic stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A registry-based study from the EBMT-LWP

Late recurrence of transfusion dependent thalassemia 30 years after transplantation

Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis

How I manage iron overload in the hematopoietic cell transplantation setting

Risk Assessment of Complications Prevalence in Italian Chelated Transfusion Dependent Thalassemia Patients

Eltrombopag Added to Standard Immunosuppressive Treatment Improves Long-Term Outcomes As Front-Line Therapy for Severe Aplastic Anemia: Final 2-Year Analysis of EBMT-Saawp Race Study

Peripheral Blood Stem Cell Versus Bone Marrow Graft for Non-T-Depleted Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Patients with Secondary Acute Myeloid Leukemia in First Complete Remission: A Study from the ALWP/EBMT

Impact of Donor Type on Outcomes after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis

Prediction of Poor Survival after Hematopoietic Cell Transplantation in Myelofibrosis Using Machine Learning Techniques

Allogeneic Transplantation for Sickle Cell Disease Offers High Rates of Cure with Low Incidence of Severe Chronic GVHD in Both Children and Adults: Real World Data from 2010-2021. An Analysis of the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Working Party

Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Retrospective Multicenter Analysis on 285 Procedures Performed between 2000 and 2020

Significant Growth in HCT Use for Haemoglobinopathies in the Last Decade Driven By Sickle Cell Disease across All Ages with Excellent Outcomes: An Analysis of EBMT Haemoglobinopathies Working Party

Better Outcome Following Younger Haploidentical Donor Versus Older Matched Unrelated Donor Transplant for Patients with Acute Myeloid Leukemia in First Remission: A Study from the Global Committee and Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Overcoming the Cost Barrier for Thalassemia Innovative Treatments

Outcomes of Patients with Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma from the LocoMMotion + MoMMent Studies

Durable Outcomes with Manageable Safety Leading to Prolonged Survival with Tagraxofusp for Treatment-Naive Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm: Updated Results from a European Named Patient Program

Impact of Fourth Methotrexate Dose in ATG-Cyclosporine GvHD Prophylaxis in HLA-Matched Unrelated HSCT: A GITMO Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only